Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Hyundai IBT Co Ltd (048410)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
20,000 -250    -1.23%
23:06:39 - Delayed Data. Currency in KRW ( Disclaimer )
Type:  Equity
Market:  South Korea
ISIN:  KR7048410005 
  • Volume: 184,819
  • Bid/Ask: 20,000 / 20,050
  • Day's Range: 19,950 - 20,550
Hyundai IBT 20,000 -250 -1.23%

048410 Balance Sheet

 
Featured here, the Balance Sheet for Hyundai IBT Co Ltd, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 15162.59 18636.29 19905.92 22229.98
Cash and Short Term Investments 11811.88 13401.95 15591.79 16459.15
Cash - - - -
Cash & Equivalents 1811.88 3401.95 4591.79 3459.15
Short Term Investments 10000 10000 11000 13000
Total Receivables, Net 465.75 2651.31 1976.44 2587.54
Accounts Receivables - Trade, Net 446.21 2258.52 1593.58 1973.24
Total Inventory 2588.14 2278.9 2037.77 2730.86
Prepaid Expenses 204.45 220.33 216.95 343
Other Current Assets, Total 92.36 83.8 82.98 109.44
Total Assets 52791.76 60845.53 62087.81 65607.53
Property/Plant/Equipment, Total - Net 2903.74 6586.37 6376.69 6586.94
Property/Plant/Equipment, Total - Gross 18862.19 22360.12 22656.79 22550.02
Accumulated Depreciation, Total -15958.44 -15773.74 -16280.1 -15963.08
Goodwill, Net - - - -
Intangibles, Net 31169.92 32941.94 32989.83 33092.46
Long Term Investments 1593.15 1469.48 1469.48 1469.48
Note Receivable - Long Term 19.54 26.79 51.86 271.3
Other Long Term Assets, Total 914.36 410.45 508.9 1221.66
Other Assets, Total 13262.76 10878.39 12312.3 14602.75
Total Current Liabilities 6946.76 7201.77 6742.7 8471.51
Accounts Payable 430.52 647.98 487.69 665.27
Payable/Accrued - - - -
Accrued Expenses 141.71 163.07 175.68 219.3
Notes Payable/Short Term Debt 5400 5400 5400 5900
Current Port. of LT Debt/Capital Leases 114.1 372.64 123.13 178.22
Other Current liabilities, Total 860.43 618.09 556.2 1508.73
Total Liabilities 7520.75 7476.94 6875.81 8588.74
Total Long Term Debt 32.43 217.94 75.88 60
Long Term Debt - - - -
Capital Lease Obligations 32.43 217.94 75.88 60
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total -4858.44 -5342.77 -5342.77 -5842.77
Total Equity 45271.01 53368.58 55212 57018.79
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 19905 19904.25 19902.25 19894.85
Additional Paid-In Capital 38827.28 38805.76 38750.22 38538.46
Retained Earnings (Accumulated Deficit) -12811.52 -4725.33 -2746.24 -408.98
Treasury Stock - Common -4.04 -4.04 -4.04 -4.04
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -645.72 -612.06 -690.2 -1001.51
Total Liabilities & Shareholders' Equity 52791.76 60845.53 62087.81 65607.53
Total Common Shares Outstanding 39.81 39.81 39.8 39.79
Total Preferred Shares Outstanding - - - -
* In Millions of KRW (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

048410 Comments

Write your thoughts about Hyundai IBT Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Gyujin Noh
Gyujin Noh Aug 19, 2021 3:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The company's antiviral drug can treat coronavirus, but it can also treat AIDS, Zika, Ebola, and the flu. It will be a revolutionary development in pharmaceutical history.
Long Short
Long Short Aug 13, 2021 10:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A medicine of this company, Hyundai Biosience, will save the world from COVID-19.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email